TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04619446

Intervention type: DEVICE
Intervention: Removable Twin Block
Description: Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia

Intervention type: DEVICE
Intervention: Fixed Functional , AdvanSync Appliance
Description: AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
Study: NCT00459680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupoint treatment
Description: Laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needle acupuncture on ST36 and LI11.
Study: NCT01250236

Intervention type: DRUG
Intervention: brimonidine 0.1%
Description: brimonidine 0.1% eye drops twice daily

Intervention type: DRUG
Intervention: placebo
Description: sodium hyaluronate 1.8mg/ml eye drops twice daily
Study: NCT01864629

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focused contraception counseling
Description: This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
Study: NCT00564135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: on Foley time
Description: A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
Study: NCT03512028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC
Description: See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle strength training
Description: All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Muscle strength training
Description: All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving training
Description: All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Driving training
Description: All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
Study: NCT04026633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAA
Description: Participants will write about the use of PBS and alcohol use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will write about eating and exercise.
Study: NCT00048932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Abatacept
Description: Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
Study: NCT03470597

Intervention type: OTHER
Intervention: dietary iodine restriction on subjects with iodine overload
Description: In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
Study: NCT00901511

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Baseline WLL
Description: Scheduled bilateral WLL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline WLL
Description: Scheduled bilateral WLL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Inhaled GM-CSF

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rescue WLL
Description: Unscheduled bilateral WLL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue WLL
Description: Unscheduled bilateral WLL
Study: NCT02847858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents
Description: School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
Study: NCT04442321

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PENS plus exercise
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PENS plus exercise
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week.
Study: NCT03074266

Intervention type: DIAGNOSTIC_TEST
Intervention: GEM Hemochron 100 ACT
Description: Activated Clotting Time

Intervention type: DIAGNOSTIC_TEST
Intervention: GEM Hemochron 100 ACT
Description: Activated Clotting Time
Study: NCT04415879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N-95 Respirator
Description: N-95 mask will be worn as personal protective equipment during a graded exercise test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N-95 Respirator
Description: N-95 mask will be worn as personal protective equipment during a graded exercise test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N-95 Respirator
Description: N-95 mask will be worn as personal protective equipment during a graded exercise test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloth Face Mask
Description: A cloth mask will be worn as personal protective equipment during a graded exercise test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloth Face Mask
Description: A cloth mask will be worn as personal protective equipment during a graded exercise test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cloth Face Mask
Description: A cloth mask will be worn as personal protective equipment during a graded exercise test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Graded exercise test
Description: No personal protective equipment during a graded exercise test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Graded exercise test
Description: No personal protective equipment during a graded exercise test
Study: NCT04622839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tylenol and NSAIDS (Ibuprofen, diclofenac)
Description: This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tylenol and NSAIDS (Ibuprofen, diclofenac)
Description: This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tylenol and NSAIDS (Ibuprofen, diclofenac)
Description: This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage.
Study: NCT04415879

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Graded exercise test
Description: No personal protective equipment during a graded exercise test
Study: NCT02798991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
Study: NCT02877082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT03931421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T treatment
Description: a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
Study: NCT01466348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Caffeine
Description: Paracetamol 1000 mg and caffeine 130 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 1000 mg
Study: NCT02798991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
Study: NCT00810901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organ Donor
Description: Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
Study: NCT03704272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SunBrite
Description: SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
Study: NCT03970733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBS (Phosphate Buffered Saline)
Study: NCT06541015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENSity 10 TENS Stimulator
Description: InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
Study: NCT01578395

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiation exposure
Description: what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiation exposure
Description: what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose radiation exposure
Description: what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose radiation exposure
Description: what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose radiation exposure
Description: what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: High-dose radiation exposure
Description: what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No radiation exposure
Description: Subjects not undergoing any radiation exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No radiation exposure
Description: Subjects not undergoing any radiation exposure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No radiation exposure
Description: Subjects not undergoing any radiation exposure
Study: NCT02729974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: rapid testing of blood clot formation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
Study: NCT04102215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEARO
Description: Robotic system for otological procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTOPLAN
Description: Otological surgical planning software
Study: NCT03130166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Use of intracorporeal anastomosis technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: Use of the conventional extracorporeal anastomosis technique
Study: NCT01059474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal DMPS
Description: 12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS.
Study: NCT03816085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoes
Description: Shoes with different heel heights

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoes
Description: Shoes with different heel heights
Study: NCT00303498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitexsentin sodium
Description: sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo identical to the study drug in description, dose and duration
Study: NCT00810901

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Prevention
Description: Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
Study: NCT04139954

Intervention type: OTHER
Intervention: There is no intervention in the study
Description: There is no intervention in the study
Study: NCT01988103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20 mg tablet BID for 68 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20 mg tablet BID for 68 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet BID for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet BID for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID for 16 weeks